| Pulmonary arterial hypertension
Adempass vs Veletri
Side-by-side clinical, coverage, and cost comparison for pulmonary arterial hypertension.Deep comparison between: Adempas vs Veletri with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVeletri has a higher rate of injection site reactions vs Adempas based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Veletri but not Adempas, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Adempas
Veletri
At A Glance
Oral
Three times daily
Soluble guanylate cyclase (sGC) stimulator
IV infusion
Continuous infusion
Prostacyclin
Indications
- Chronic thromboembolic pulmonary hypertension
- Pulmonary arterial hypertension
- Pulmonary arterial hypertension
Dosing
Chronic thromboembolic pulmonary hypertension, Pulmonary arterial hypertension Start at 1 mg three times a day (or 0.5 mg if hypotension risk); increase by 0.5 mg no sooner than every 2 weeks as tolerated, to a maximum of 2.5 mg three times a day.
Pulmonary arterial hypertension Initiate continuous IV infusion at 2 ng/kg/min via central venous catheter; increase in increments of 2 ng/kg/min every 15 minutes or longer until tolerance limit established or further increases are not clinically warranted; adjust maintenance dose by 1- to 2-ng/kg/min increments at intervals of at least 15 minutes based on symptom persistence or adverse events.
Contraindications
- Pregnancy
- Concomitant use of nitrates or nitric oxide donors in any form
- Concomitant use of PDE-5 inhibitors (sildenafil, tadalafil, or vardenafil) or nonspecific PDE inhibitors (dipyridamole or theophylline)
- Concomitant use of other soluble guanylate cyclase (sGC) stimulators
- Pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP)
- Chronic use in patients with congestive heart failure due to severe left ventricular systolic dysfunction
- Pulmonary edema developing during dose initiation (associated with pulmonary veno-occlusive disease)
- Known hypersensitivity to epoprostenol or structurally related compounds
Adverse Reactions
Most common (>=3%) Headache, dyspepsia and gastritis, dizziness, nausea, diarrhea, hypotension, vomiting, anemia, gastroesophageal reflux disease, constipation
Serious Embryo-fetal toxicity, hypotension, bleeding
Most common (dose initiation and escalation) Flushing, headache, nausea, vomiting, hypotension, anxiety, chest pain, dizziness, bradycardia, abdominal pain, musculoskeletal pain, dyspnea, tachycardia
Most common (chronic dosing) Headache, jaw pain, flushing, diarrhea, nausea, vomiting, flu-like symptoms, anxiety
Postmarketing Anemia, hypersplenism, pancytopenia, splenomegaly, high output cardiac failure, hyperthyroidism
Pharmacology
Riociguat is a soluble guanylate cyclase (sGC) stimulator with a dual mode of action: it sensitizes sGC to endogenous nitric oxide (NO) by stabilizing the NO-sGC binding, and directly stimulates sGC via a separate binding site independently of NO, increasing cGMP generation and leading to vasodilation.
Epoprostenol is a naturally occurring prostacyclin (metabolite of arachidonic acid) that produces direct vasodilation of pulmonary and systemic arterial vascular beds, reducing right- and left-ventricular afterload and increasing cardiac output, and inhibits platelet aggregation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Adempas
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Veletri
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Adempas
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (6/8)
Veletri
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Adempas
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Veletri
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAdempas Co-pay Assistance Program
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: MPS II- Hunter Syndrome
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AdempasView full Adempas profile
VeletriView full Veletri profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.